Authors
Latest:
Target Switch and High-Risk Cohorts Support Talquetamab Use in RRMMDuring a Case-Based Roundtable® event, Omar Nadeem, MD, and participants reacted to data from the MonumenTAL-1 trial in the first article of a 2-part series.
Latest:
Tailoring Regimens for Different Age Groups With Multiple MyelomaDuring a Case-Based Roundtable® event, Andrew Yee, MD, discussed myeloma treatment strategies for different age groups, focusing on personalized regimens and the pros and cons of CAR T-cell therapy and bispecific antibodies in the second article of a 2-part series.
Latest:
Roundtable Discussion: Dietrich and Santos Look at Targeted Treatments for Patients With NSCLCA 72-year-old White man presented with chest pain, cough, and dyspnea. He had a medical history of type 1 diabetes that was adequately controlled, and was a former smoker.
Latest:
GRIFFIN Follow-Up Shows Promising Responses With Daratumumab plus VRDUpdated results of the GRIFFIN trial revealed that the addition of daratumumab to a standard-of-care regimen used in the treatment of newly diagnosed multiple myeloma met the trials primary end point of higher rates of stringent complete response in patients who are eligible for transplant.
Latest:
FDA Considers New Warning and Label Recommendations for Breast ImplantsAccording to a statement from the FDA, the agency has issued a draft guidance proposing labeling recommendations for breast implant manufacturers that would help patients understand the benefits and risks of implants. The labeling recommendations would include the addition of a boxed warning.
Latest:
Less is More With Lymph Node Surgery in Breast CancerTari King, MD, chief of Breast Surgery, Dana-Farber/Brigham and Women's Cancer Center, discusses a "less is more" approach when it comes to lymph node surgery in patients with breast cancer.
Latest:
ECHELON-1 Trial Shows Continued Efficacy Over Time in Hodgkin LymphomaTatyana Feldman, MD, discusses the design and efficacy of the ECHELON-1 trial investigating brentuximab vedotin with chemotherapy in patients with stage III or IV Hodgkin lymphoma after a 3-year update.
Latest:
Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal CancerTo determine the frequency and clinical characteristics of parotid gland metastasis from nasopharyngeal cancer and oropharyngeal cancer and define criteria for elective inclusion of parotidean nodes in the radiotherapy clinical target volume.
Latest:
DNA Testing for Breast Cancer Risk: What the Current Medical Evidence Tells UsWhile predictive genetic testing is useful and even crucial for many populations, new medical advances are routinely overhyped in the media and misunderstood by consumers and providers alike.
Latest:
Anti-TIGIT and ICI Combinations Supported by Early-Phase ResearchApproaches that pair anti-TIGIT antibodies with other immune checkpoint inhibitors have sparked interest among investigators. Results of early-stage studies evaluating these unique combinations were recently presented at the American Association for Cancer Research Annual Meeting 2021. Later-stage studies are ongoing.
Latest:
IDH Mutations Offer Hope as a Prognostic Indicator and Treatable Target in GliomasSeveral presentations at the 2019 American Society of Clinical Oncology Annual Meeting highlighted a hopeful new direction in the treatment of gliomas, demonstrating the relevance of <em>IDH1/2</em> mutational status and its feasibility as a target of therapy.
Latest:
Moving Forward With Results From CheckMate-142 in MSI-H mCRCThierry Andre, MD, professor of medical oncology at the University Pierre et Marie Curie (UMPC) and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique H&ocirc;pitaux in Paris, discusses the introduction of immunotherapy to the treatment landscape of metastatic colorectal cancer.
Latest:
An Overview of a Practice-Changing Trial With mFOLFIRINOX in Pancreatic CancerThierry Conroy, MD, a medical oncologist and director at the Institut de Cancerologie de Lorraine in Nancy, France, shares some background on the PRODIGE 24/CCTG PA.6 trial where a modified FOLFIRINOX regimen was found superior to the adjuvant standard of care, gemcitabine, in patients with resected pancreatic cancer.
Latest:
ACCC President Reignites Resilience in Oncology CaregiversThomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to “reflect, renew, and reignite” in order to create a more resilient oncology team for the community.
Latest:
Unmet Needs and Future Directions for Ovarian CancerThomas C. Krivak MD, John K. Chan, MD, and Cecelia H. Boardman, MD, share insight on recent updates to maintenance therapy, unmet needs, and the future treatment landscape for ovarian cancer.
Latest:
Dr. Thomas Churilla on Insured Versus Uninsured Patients With Head and Neck Cancer Getting TreatmentChurilla said the majority of patients on a national level had insurance, with only 15% of patients utilizing medicaid and 5% of patients being uninsured.
Latest:
Treating Patients With RCC Who Progress Following Adjuvant TherapyThe expert panel concludes with insights on the treatment of patients with renal cell carcinoma who progress following adjuvant therapy.
Latest:
Issues Still to be Addressed in Diffuse Large B-Cell LymphomaThomas E. Witzig, MD, hematologist-oncologist, Mayo Clinic, discusses some of the issues that still need to be addressed in diffuse large B-cell lymphoma.
Latest:
Nab-Sirolimus Yields Long-Lasting Benefits Across PEComa SubgroupsThomas J. Herzog, MD, discusses the efficacy data seen in a subgroup analysis of the phase 2 AMPECT study evaluating nab-Sirolimus for patients with perivascular epithelioid sarcoma.
Latest:
Treating Patients With T790M-Mutant NSCLCThomas J. Lynch, MD, discusses the treatment of patients with T790M-mutant non-small cell lung cancer (NSCLC).
Latest:
Results of a Phase II Study of Palbociclib in Esophageal and Gastric CancerThomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced <br /> esophageal or gastric cancer.<br />
Latest:
Study of Cemiplimab Use in Hepatocellular Carcinoma Meets Primary End PointsThomas Marron, PhD, MD, discusses the end points of an exploratory study which examines the use of cemiplimab in hepatocellular carcinoma.
Latest:
The Role of Circulating Tumor DNA in Bladder CancerFollowing a discussion centered on the EV-302 study, Thomas Powles, MBBS, MRCP, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in urothelial cancer.
Latest:
Dr. Thomas Stinchcombe on Targeted Therapies in Squamous Cell Lung CancerThomas Stinchcombe, MD, discusses the complicated nature of squamous cell lung cancer. Stinchcombe says that there has been a recent boom in targeted therapies for non-squamous cell lung cancer, though not as much research in squamous cell lung cancer due to its multitude of mutations.
Latest:
Updates in the Bladder Cancer Space Lead to Changes in NCCN GuidelinesThomas Flaig, MD, discusses recent updates seen in the bladder cancer space and how they have led to changes to the NCCN guidelines.
